CRANFORD, N.J. , July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The... Read More

CRANFORD, N.J. , July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The... Read More

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J. , July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the execution of a distribution services agreement with Cencora... Read More

CRANFORD, N.J. , June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), are nearing completion. The... Read More

CRANFORD, N.J. , May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc . ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025 . "In Q2 2025, Citius Oncology advanced its transformation from a development-stage... Read More

CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024 . Fiscal First Quarter 2025 Business Highlights and Subsequent Developments... Read More

CRANFORD, N.J. , Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on... Read More

CRANFORD, N.J. , Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. The engagement of Jefferies underscores... Read More

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full... Read More

CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S.... Read More

CEO Leonard Mazur to present on Tuesday, September 10, 2024 , at 9:00 am ET CRANFORD, N.J. , Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City... Read More

LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, Inc. anticipated to begin trading on Nasdaq under the ticker "CTOR" on August 13, 2024 CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage... Read More

Management call scheduled for Tuesday, August 13, 2024 , at 8:30 AM ET CRANFORD, N.J. , Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc . ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur , will be joined by members of the management team.... Read More

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (“TenX”), a publicly traded special purpose acquisition company, was... Read More

Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval marks the first novel targeted systemic therapy approved by the FDA r/r CTCL since 2018 Approval based on Phase 3 Pivotal Study 302 results that demonstrated 36% ORR, reduction in skin disease in 84% of patients, clinically... Read More

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq:... Read More

Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J. , Aug. 5, 2024... Read More

Multiple catalysts for potentially transformative assets in second half of 2024 Strong momentum expected from positive topline results of Phase 3 Mino-Lok ® trial, commercialization of LYMPHIR™ if approved First-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantage Financial... Read More

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J. , May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline... Read More

Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates statistically significant overall success of Mino-Lok therapy with a greater percentage of patients retaining their catheters (p=0.0025) CRANFORD, N.J. , May 21, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and... Read More

Mino-Lok data analysis on track with topline results anticipated this quarter LYMPHIR biologics license application accepted with PDUFA target action date set for August 13, 2024 CRANFORD, N.J. , May 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products... Read More

CRANFORD, N.J. , May 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual... Read More

CRANFORD, N.J. , April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has closed its previously announced registered direct offering for the purchase of an aggregate of 21,428,574 shares of its common stock and... Read More

CRANFORD, N.J. , April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase... Read More

National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA , to participate in the University of Minnesota (UMN) Masonic Cancer Center's ongoing Phase 1 trial to determine the maximum tolerated dose of LYMPHIR plus CAR-T therapy CRANFORD, N.J. , April 11, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical... Read More

CRANFORD, N.J. , April 4, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference being held April 8-9, 2024 , in New York City.... Read More

FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024 CRANFORD, N.J. , March 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the U.S. Food and Drug Administration (FDA) has accepted the... Read More

Net operating losses converted into non-dilutive capital CRANFORD, N.J. , March 7, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the Company has received $2.4 million in non-dilutive capital through New Jersey's Technology... Read More

CRANFORD, N.J. , Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company filed a Form S-3 shelf registration on February 23, 2024 with the Securities and Exchange Commission to replace its currently effective shelf... Read More

CRANFORD, N.J. , Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will present at the BIO CEO and Investor Conference on February... Read More

Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial CRANFORD, N.J. , Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results... Read More

FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission CRANFORD, N.J. , Feb. 13, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the... Read More

Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD, N.J. , Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the nomination of seasoned pharmaceutical executive Robert J.... Read More

Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibiotic lock solution in development to salvage catheters in patients with CRBSI CRANFORD, N.J. , Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of... Read More

Mino-Lok ® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 CRANFORD, N.J. , Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial... Read More

CRANFORD, N.J. , Nov. 9, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on November 15, 2023 . Conference Details: Presentation: 11 :30 am ET, Wednesday, November 15, 2023... Read More

Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor microenvironment CRANFORD, N.J. , Oct. 31, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that preclinical research on LYMPHIR ("denileukin diftitox" or... Read More

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transaction anticipated to close in the first half of 2024 CRANFORD, N.J. and NEW YORK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company... Read More

CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir , a long-time member of the... Read More

CRANFORD, N.J. , Sept. 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir , who passed away on Monday. Mr. Safir joined the Citius Board of Directors in 2014, providing invaluable counsel to the Citius management team for nearly a decade. "We are deeply saddened to announce the passing of our friend and longtime board member,... Read More

Resubmission to FDA planned for early 2024 CRANFORD, N.J. , Sept. 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance from the U.S. Food and Drug Administration (FDA) regarding the planned resubmission of the Company's Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox), an engineered... Read More

CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023 . Citius Chairman and CEO Leonard Mazur will present at the H.C. Wainwright 25th Annual Global... Read More

$33.3 million in cash and cash equivalents as of June 30, 2023 ; runway through August 2024 CRANFORD, N.J. , Aug. 14, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter ended June... Read More

CRANFORD, N.J. , Aug. 10, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has reached an important milestone in its clinical trial for Mino-Lok ® , an antibiotic lock solution to salvage catheters in patients with... Read More

No clinical efficacy or safety issues raised Citius committed to working toward approval CRANFORD, N.J. , July 29, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the Company's Biologics License Application (BLA) seeking approval for denileukin diftitox ("LYMPHIR TM "),... Read More

CRANFORD, N.J. , June 26, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it is set to be added to the broad-market Russell 3000 ® Index and the small-cap Russell 2000 ® Index at the conclusion of the annual reconstitution of Russell US Indexes,... Read More

CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the FDA Trial validates Patient Reported Outcome (PRO) instrument developed to support a pivotal Phase 3 study CRANFORD, N.J. , June 20, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR) today... Read More

CRANFORD, N.J. , June 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc . ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will participate in a fireside chat with Senior Biotech Research Analyst, Michael Okunewitch , at Maxim Group's Virtual... Read More

$29.1 million in cash and cash equivalents as of March 31, 2023 ; $15 million registered direct offering in May 2023 extends runway through May 2024 Halo-Lido Phase 2b trial completed with topline results anticipated by end of calendar Q2 2023 CRANFORD, N.J. , May 12, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the... Read More

CRANFORD, N.J. , May 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered direct offering with certain healthcare-focused and institutional investors for the purchase of an aggregate of... Read More

CRANFORD, N.J. , May 4, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 12,500,001 shares of... Read More

CRANFORD, N.J. , April 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has advanced its clinical trial for Mino-Lok ® , an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream... Read More

Topline Results anticipated by the end of Q2 2023 CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. CITI-002 would be the first prescription product indicated for the treatment of... Read More

CRANFORD, N.J. , March 30, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate... Read More

CRANFORD, N.J. , March 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class... Read More

CRANFORD, N.J. , March 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California . Citius Chairman and CEO Leonard Mazur will host... Read More

$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024 Uptick in patient recruitment for Mino-Lok® Phase 3 trial Halo-Lido Phase 2b trial nearing completion CRANFORD, N.J. , Feb. 10, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class... Read More

CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 . Conference Details: Date: Wednesday, January... Read More

$41.7 million in cash and cash equivalents as of September 30, 2022 ; extends runway through December 2023 Mino-Lok® Phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review I/ONTAK BLA accepted for filing by the FDA; updated PDUFA target action date is July 28, 2023 Halo-Lido Phase 2b trial progressed; data readout expected 2H 2023 Multiple... Read More

Prescription Drug User Fee Act (PDUFA) target action date is September 28, 2023 CRANFORD, N.J. , Dec. 1, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Biologics License... Read More